Co-Director Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical Center; Own tweets not reflective of employer or industry; LFGM
Joined November 2022
- Tweets72
- Following104
- Followers166
- Likes113
Ethan Rowin retweeted
Should midventricular obstruction be considered a distinct HCM phenotype? @ASchulzMD et al. show it’s associated with a nearly 2-fold #HeartFailure risk at 5 years vs nonobstructive HCM.
More in #JACC: bit.ly/4hZNBuc
@EthanRowin @IacopoOlivotto @MattinMaronMD @lhpeng
Atrial fibrillation recurrence rates in HCM. High rates of recurrence across multiple rhythm control treatment pathways highlighting need for HCM specific AF treatments/ study.
mdpi.com/4132572
@MDPIOpenAccess
Ethan Rowin retweeted
We presented the ACACIA-HCM trial. A milestone for us and our patients, having a therapy that influences many important clinical domains that are relevant to patients and physicians alike.
This is the start in nHCM. An impactful one.
Paper simultaneously published in @NEJM
nejm.org/doi/full/10.1056/NE…
#cardiotwitter
#ESC2026
#ESCCongress
#ESCCongress2026
Ethan Rowin retweeted
Atrial fibrillation recurrence and outcomes in patients with hypertrophic cardiomyopathy: Insights from a nationwide real-world cohort
@AmroAglanMD @WMCHealth @EthanRowin @LaheyHospital
heartrhythmjournal.com/artic…
Ethan Rowin retweeted
Atrial fibrillation in hypertrophic cardiomyopathy: A unique clinical entity requiring dedicated study #OpenAccess
@EthanRowin @MasriAhmadMD
heartrhythmjournal.com/artic…
Ethan Rowin retweeted
AF management in #HCM is still evolving fast—and #PFA is at the center of the debate. Saturday at #HCM9, @konsiont makes the case for pulsed field ablation as the new gold standard; @EthanRowin makes the case for drug therapy. Then it's open floor—bring your questions. #AFib
ALT The International HCM Summit (9th edition) session titled 'A Focus on Atrial Fibrillation.' Features photos of Dr. Konstantinos Siontis speaking on 'PFA in HCM: The New Gold Standard for AF Treatment?' and Dr. Ethan Rowin speaking on 'Predicting and Managing AF, Including the Potential for Novel Drug Therapy.' Event details: Saturday, October 24, 2026, 4:50 PM ET, Boston, hcmsummit.org.
Very appreciative of the collaboration with the HCM centers at University of Toronto, NYU, MGH, Florence, Tufts, Amrita, Spectrum Grand Rapids, Imperial College, Hopkins and Lahey that made this possible.
Clinical spectrum and outcomes in HCM with LV Apical Aneurysms: A large multicenter international cohort
500+ patient analysis describing the natural history of this HCM phenotype and examining relationship with size.
sciencedirect.com/science/ar…
Clinical spectrum and outcomes in HCM with LV Apical Aneurysms: A large multicenter international cohort
500+ patient analysis describing the natural history of this HCM phenotype and examining relationship with size.
sciencedirect.com/science/ar…
Ethan Rowin retweeted
Many #HCM patients who die suddenly could have been saved. Risk stratification and device selection are where we win or lose that fight. We deep dive on it all in Friday's program: @EthanRowin, #JuanPabloKaski & @ExtraStim.
Join us ➡️ hcmsummit.org #HCMSummit9 #SCD
Ethan Rowin retweeted
Real-world mavacamten use in obstructive HCM reveals racial disparities and higher risk in patients with atrial fibrillation. @AymanFathMD1 @islamelgendy83 @EthanRowin @UTHealthSA ahajrnls.org/3QSODgB
Ethan Rowin retweeted
Atrial fibrillation recurrence and outcomes in patients with hypertrophic cardiomyopathy: Insights from a nationwide real-world cohort
@AmroAglanMD @WMCHealth @EthanRowin @LaheyHospital
heartrhythmjournal.com/artic…
Ethan Rowin retweeted
Our new @JAHA_AHA paper on real-world outcomes of mavacamten in HCM.
ahajournals.org/doi/10.1161/…
In >15K obstructive HCM pts, 3.5% were on mavacamten. Black pts were ~55% less likely to receive it. Afib predicted higher-risk & worse outcomes.
@AmroAglanMD @EthanRowin @MartinMaronMD
An important unmet need within hypertrophic cardiomyopathy and an area which we need more dedicated investigation. Privileged to work on this with an outstanding group of co-authors highlighting the differences of AF in HCM
Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Unique Clinical Entity Requiring Dedicated Study #OpenAccess
@EthanRowin @MasriAhmadMD
heartrhythmjournal.com/artic…
Ethan Rowin retweeted
Lahey Hospital and Medical Center is currently looking to hire a structural fellow for the 2026-2027 academic year. Join a collegial and busy team with large volumes that is always coming up with creative solutions! If you would like to apply, please message me.
Ethan Rowin retweeted
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials #OpenAccess
@EthanRowin @LaheyHospital
heartrhythmjournal.com/artic…
Ethan Rowin retweeted
In obstructive #HCM, #pVO2, #NYHA, and #KCCQ don’t always align!
Weak correlations and frequent patient-level discordance raise considerations for optimal metric selection in clinical practice and clinical trial design.
🔗kwnsfk27.r.eu-west-1.awstrac…
Ethan Rowin retweeted
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials #OpenAccess
@EthanRowin @LaheyHospital
heartrhythmjournal.com/artic…
Ethan Rowin retweeted
We presented long-term data from #FOREST #HCM on the incidence and impact of atrial fibrillation in patients treated with aficamten in the Cardiomyopathy LBCT session
Led by @EthanRowin
#ESC2025
#CardioTwitter
Ethan Rowin retweeted
Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy #OpenAccess
@EthanRowin @MartinMaronMD
heartrhythmjournal.com/artic…
